Innovative SALDI mass spectrometry analysis for Alzheimer's disease synthetic peptides detection.

[1]  S. Lehmann,et al.  Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort , 2023, Alzheimer's Research & Therapy.

[2]  K. Blennow,et al.  Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[3]  D. Mousseau,et al.  The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression , 2021, Scientific reports.

[4]  S. Lehmann,et al.  MALDI‐TOF IP‐MS quantification of plasma amyloid peptides in Alzheimer’s disease , 2020 .

[5]  A. Fagan,et al.  Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[6]  G. Frisoni,et al.  Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study , 2019, Alzheimer's Research & Therapy.

[7]  J. Trojanowski,et al.  Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays , 2019, Scientific Reports.

[8]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[9]  K. Blennow,et al.  Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status , 2019, JAMA neurology.

[10]  Molly M Stevens,et al.  Porous Silicon Nanoneedles Modulate Endocytosis to Deliver Biological Payloads , 2019, Advanced materials.

[11]  N. Tang,et al.  Aβ42/Aβ40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[12]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[13]  D. Rujescu,et al.  Amyloid blood biomarker detects Alzheimer's disease , 2018, EMBO molecular medicine.

[14]  Y. Coffinier,et al.  Gold nanoparticles coated silicon nanowires for efficient catalytic and photocatalytic applications , 2018 .

[15]  J. Trojanowski,et al.  CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts , 2018, Alzheimer's & Dementia.

[16]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[17]  Bernhard Hemmer,et al.  Consensus guidelines for lumbar puncture in patients with neurological diseases , 2017, Alzheimer's & dementia.

[18]  Y. Coffinier,et al.  Hydrothermal preparation of MoS2/TiO2/Si nanowires composite with enhanced photocatalytic performance under visible light , 2016 .

[19]  K. Blennow,et al.  Plasma β-amyloid in Alzheimer’s disease and vascular disease , 2016, Scientific Reports.

[20]  Erin E. Chambers,et al.  Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry , 2016, Alzheimer's & Dementia.

[21]  E. Tasciotti,et al.  Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. , 2015, Nature materials.

[22]  Ciro Chiappini,et al.  Biodegradable nanoneedles for localized delivery of nanoparticles in vivo: exploring the biointerface. , 2015, ACS nano.

[23]  K. Dzierzbicka,et al.  A study on the protection of methionine and the reduction of methionine sulfoxide in methionine-containing analogues of the growth-modeling factor Gly-His-Lys , 2015 .

[24]  Y. Coffinier,et al.  Decoration of silicon nanostructures with copper particles for simultaneous selective capture and mass spectrometry detection of His-tagged model peptide. , 2014, The Analyst.

[25]  Rabah Boukherroub,et al.  The antimicrobial effect of silicon nanowires decorated with silver and copper nanoparticles , 2013, Nanotechnology.

[26]  M. Carrillo,et al.  CSF biomarker variability in the Alzheimer's Association quality control program , 2013, Alzheimer's & Dementia.

[27]  Jie-Bi Hu,et al.  Coffee-ring effects in laser desorption/ionization mass spectrometry. , 2013, Analytica chimica acta.

[28]  Jacob T. Robinson,et al.  Vertical silicon nanowires as a universal platform for delivering biomolecules into living cells , 2010, Proceedings of the National Academy of Sciences.

[29]  R. Arakawa,et al.  Detailed Investigation on the Possibility of Nanoparticles of Various Metal Elements for Surface-Assisted Laser Desorption/Ionization Mass Spectrometry , 2009, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[30]  M. Coelho,et al.  Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide. , 2008, Biophysical chemistry.

[31]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[32]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[33]  Yu-Chie Chen,et al.  Affinity-based mass spectrometry using magnetic iron oxide particles as the matrix and concentrating probes for SALDI MS analysis of peptides and proteins , 2006, Analytical and bioanalytical chemistry.

[34]  M. Shiao,et al.  The Effect of Aβ Conformation on the Metal Affinity and Aggregation Mechanism Studied by Circular Dichroism Spectroscopy , 2006 .

[35]  J. Pettegrew,et al.  Alzheimer’s Disease: Soluble Oligomeric Aβ(1–40) Peptide in Membrane Mimic Environment from Solution NMR and Circular Dichroism Studies , 2004, Neurochemical Research.

[36]  B. Brooks,et al.  Oxidation of methionine residues in aqueous solutions: free methionine and methionine in granulocyte colony-stimulating factor. , 2004, Journal of the American Chemical Society.

[37]  C. Masters,et al.  Methionine oxidation: Implications for the mechanism of toxicity of the β-amyloid peptide from Alzheimer's disease , 2003, Letters in Peptide Science.

[38]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[39]  S. Lin,et al.  Temperature-induced conformational changes in amyloid beta(1-40) peptide investigated by simultaneous FT-IR microspectroscopy with thermal system. , 2001, Biophysical chemistry.

[40]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Selkoe.  Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease , 1993, Trends in Neurosciences.

[42]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[43]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[44]  C. Barrow,et al.  Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.

[45]  J. Reed,et al.  Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease , 1991 .

[46]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Asmus,et al.  Mechanism of the hydroxyl radical induced oxidation of methionine in aqueous solution , 1981 .

[48]  C. Teunissen,et al.  Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. , 2019, Methods in molecular biology.

[49]  K. Blennow,et al.  Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[50]  A. Ruiz,et al.  Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer’s Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study , 2018, The Journal of Prevention of Alzheimer's Disease.

[51]  C. Jack,et al.  Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .